Lupin Limited, an innovation-led transnational pharmaceutical company headquartered in Mumbai, announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag facility. The inspection for the API facility was conducted by the U.S. FDA between January 13, 2020 and…